FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

Share this content:
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

TUESDAY, June 5, 2018 (HealthDay News) -- The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.

A biosimilar drug, generally derived from a living organism, is approved based on clinical evidence that it is "highly similar" to a product that's already approved by the FDA, and that there are "no clinically meaningful differences" in safety, purity and potency, the agency said.

The most common side effects of Fulphila are pain in the bones, arms and legs. Less common but more serious adverse reactions include the possibility of spleen rupture, severe respiratory problems and allergic reactions, glomerulonephritis, leukocytosis, tumor growth, and "fatal sickle cell crises," the FDA said.

"We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from [price] competition to existing biologics once lawful intellectual property has lapsed on these products," FDA Commissioner Scott Gottlieb, M.D., said in a statement.

Fulphila is produced by Mylan, with U.S. headquarters in Canonsburg, Penn.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WPSI Recommends Annual Urinary Incontinence Screening

WPSI Recommends Annual Urinary Incontinence Screening

Due to limited evidence, other experts urge caution in implementing guideline for women

Young, Growing Athletes at High Risk for ACL Injuries

Young, Growing Athletes at High Risk for ACL ...

Athletic teams should provide program that includes muscle strengthening, proper technique training

Side Effects of Biologics for Rheumatic Dz May Up Anxiety

Side Effects of Biologics for Rheumatic Dz May ...

Common patient concerns are risks of cancer and tuberculosis activation

is free, fast, and customized just for you!




Already a member?

Sign In Now »